{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:26Z","timestamp":1794047486772,"version":"4.8.0"},"reference-count":13,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2024.285893","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T03:35:27Z","timestamp":1729136127000},"page":"753-757","source":"Crossref","is-referenced-by-count":4,"title":["Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States"],"prefix":"10.3324","volume":"110","author":[{"given":"Malin","family":"Hultcrantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kleinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Delforge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali","family":"Kotowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Bitetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Boytsov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Camadoo-O'Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey Powers","family":"Happ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Mahendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"73436","doi-asserted-by":"crossref","unstructured":"Tai YT, Mayes PA, Acharya C. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-3138.","DOI":"10.1182\/blood-2013-10-535088"},{"key":"73437","unstructured":"US Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. 2020."},{"key":"73438","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21(2):207-221.","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"73439","unstructured":"European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023."},{"key":"73440","unstructured":"US Food and Drug Administration. Announcement of the revocation of the biologics license for BLENREP. 2023."},{"key":"73441","doi-asserted-by":"crossref","unstructured":"Rifkin RM, Boyd K, Grosicki S. DREAMM-7: a phase III study of the efficacy and safety of belantamab mafodotin (Belamaf) with bortezomib, and dexamethasone (B-Vd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020; 136(Supplement 1):53-54.","DOI":"10.1182\/blood-2020-139181"},{"key":"73442","doi-asserted-by":"crossref","unstructured":"Trudel S, Davis R, Lewis NM. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020; 136(Supplement 1):4.","DOI":"10.1182\/blood-2020-139785"},{"key":"73443","doi-asserted-by":"crossref","unstructured":"Trudel S, McCurdy A, Louzada ML. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial. Nat Med. 2024; 30(2):543-551.","DOI":"10.1038\/s41591-023-02703-y"},{"key":"73444","doi-asserted-by":"crossref","unstructured":"Hungria V, Robak P, Hus M. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2024; 391(5):393-407.","DOI":"10.1056\/NEJMoa2405090"},{"key":"73445","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Beksac M, Pour L. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N Engl J Med. 2024; 391(5):408-421.","DOI":"10.1056\/NEJMoa2403407"},{"key":"73446","unstructured":"US Food and Drug Administration. BLENREP. Highlights of prescribing information. 2020."},{"key":"73447","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023; 10(10):e801-e812.","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"73448","doi-asserted-by":"crossref","unstructured":"Nooka AK, Cohen AD, Lee HC. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023; 129(23):3746-3760.","DOI":"10.1002\/cncr.34987"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285893\/77624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285893\/78127","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11788\/77624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:28Z","timestamp":1794046048000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285893","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}